Split doses of Methotrexate in patients with moderate to severe Psoriasis

Rodríguez-Zúñiga, Milton José Max; Cortez-Franco, Florencio; Qujiano-Gomero, E.

doi:10.1016/j.adengl.2016.12.024

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The AUC 0-10 h was not primarily dependent on the administration route. Rodr ıguez-Z uñiga et al 21 reported that enteral and parenteral divided doses given weekly seem to show similar efficacy.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the clinical efficacy of subcutaneous vs. oral administration of methotrexate in patients with psoriasis vulgaris: a randomized controlled trial

Choonhakarn

Chaowattanapanit

Julanon

et al. 2022

Clin Experimental Derm

View full text Add to dashboard Cite

Summary Background Evidence demonstrates that parenteral administration of methotrexate (MTX) has a higher drug bioavailability than oral administration. This difference is even more pronounced for medium to high dosages. Aim To compare the efficacy, safety, and tolerability of oral and subcutaneous (SC) MTX for treatment of psoriasis. Methods A randomized, comparative, single‐blind, 32‐week study was conducted. The clinical response was evaluated using the Psoriasis Area Severity Index (PASI) and patient global satisfaction was assessed using a visual analogue scale (VAS). Results In total, 77 completed the study: 38 in the SC and 39 in the oral MTX group. No significant between‐group differences were found in the number attaining PASI improvement of 75% (PASI75), 90% (PASI90) and 100% (PASI100) at Weeks 16 and 32: PASI75 (P = 0.14 and P = 0.21, respectively), PASI90 (P = 0.23 and P = 0.18) and PASI100 (P = 0.62 and P = 0.22). According to the mean VAS, no significant differences between the groups were found at any time points except at Week 32 that the mean VAS was significantly higher in the SC group (P = 0.03). Adverse events were comparable in both groups. Conclusion SC and oral administration of MTX had similar efficacies in improving the PASI score even at the highest tolerable dose; however, the SC MTX group had higher overall patient satisfaction than the oral MTX group. No difference in tolerability was found.

show abstract

Section: Discussionmentioning

confidence: 99%